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cancers. The evidence is promising, and
the possibilities wide open.
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A recent report in Science from the Varmus laboratory (Podsypanina et al., 2008) puts an interesting twist on
the origins of metastatic cells, suggesting that metastases can arise in ways that are very different from those
widely believed.Cancer Cell 14, October 7, 2008 ª2008 Elsevier Inc. 283The accepted canon of tumor progression
involves the initial development of tumor-
igenicity by cells within the site of primary
tumor formation. These cells remain in
that site unless they become invasive,
with an associated tendency to intrava-
sate (enter blood vessels) and dissemi-
nate via the circulation to distant sites in
the body. Subsequently, disseminated
cells may escape blood vessels (extrava-
sate), form micrometastases, and, with
very low efficiency, succeed in forming
macroscopic metastases (colonization)
(Fidler, 2002, 2003; Fidler et al., 2007;
Thiery, 2002).
The factors that enable the neoplastic
cells within primary tumors to invade and
metastasize are surely complex. Some
of these determinants may already be
implanted in the precursors of primary
tumor cells relatively early in the courseof tumor progression. For example, the
differentiation program of a normal cell
of origin as well as the spectrum of so-
matic alterations (mutations and promoter
methylation events) sustained by its lineal
descendants within a primary tumor are
both likely to affect the probability of
evolving highly malignant cell traits (Ber-
nards and Weinberg, 2002; Ince et al.,
2007). In addition, the stromal microenvi-
ronment of a primary carcinoma is also
likely to contribute heterotypic signals
that influence the eventual development
of invasive traits (Bhowmick et al., 2004).
Once these various factors converge on
individual tumor cells and impart to them
an invasive phenotype, these cells may
gain ready access to the systemic circula-
tion, providing them with channels that
carry them to distant sites in the body.
More often than not, the destination sitesare likely to be dictated by the accidental
trapping of relatively large cancer cells in
the small-diameter microvessels present
in most organs. The lung is a favored
site of initial dissemination, as its capillary
bed is the first encountered by circulating
tumor cells after they have entered into
the venous circulation and made an initial
pass through the heart.
Most cells (>95%) are cleared from sites
of initial trapping in the lungs (for example)
within a day or two. Moreover, the fate of
the survivors that succeed in extravasating
is hardly clear. Some may survive as indo-
lentmicrometastases for extendedperiods
of time without losing their viability, while
most eventually disappear. Only on very
rare occasions do the cells in micrometa-
stases succeed in proliferating vigorously
and forming a macroscopic metastasis—
the colonization process (Fidler, 2003).
Cancer Cell
PreviewsIn fact, we have only fragmentary knowl-
edge of how cancer cells learn to colonize
foreign tissue sites. Some may be en-
dowed with this ability even prior to their
leaving a primary tumor—an accidental
byproduct of primary tumor progression.
More frequently, however, it seems likely
that cancer cells develop colonizing ability
in sites of dissemination, where this
phenotype is strongly selected. Once col-
onizing ability has been acquired, the
resulting macroscopic metastases can
now become sources for broadcasting
a new wave of metastatic cells. The cells
released in this secondary ‘‘shower’’ may
be the most dangerous cells of all: they
are doubly endowed, having the ability to
both disseminate and colonize.
The acquired ability to colonize is likely
to involve significant changes in cell
phenotype that depend in turn on multiple
changes in the genetic and epigenetic
regulators of cell proliferation, motility,
and invasiveness. This realization pro-
vokes another still unanswered question:
Do the cells in disseminated micrometa-
stases need to undergo many growth-
and-division cycles over extended pe-
riods of time in order to generate the
genetic variability that is needed in turn
for the development of novel, malig-
nancy-associated phenotypes?
Some of these issues come into play in
a recent paper by Podsypanina et al.
(2008). The authors developed mice with
transgenes containing doxycycline-acti-
vatable myc and ras oncogenes. When
fed doxycycline, these mice expressed
the two oncogenes specifically in the
mammary epithelium and developed
diffuse mammary tumors within a period
of 3 to 4 weeks. The authors turned the
normal sequence of tumor progression
on its head by injecting normal mouse
mammary cells into the venous circulation
and only activating the transgenes after
these cells had lodged in the capillary
beds of the lung. Hence, the cells initially
arriving in the lungs were phenotypically
normal and only acquired tumorigenic
ability following their dissemination.
Such tail-vein injection, often termed
‘‘experimental metastasis,’’ circumvents
the initial steps of the invasion-metastasis
cascade, specifically local invasion at
the site of primary tumor formation and
intravasation. Direct introduction into
a tail vein—the normally preferred site in284 Cancer Cell 14, October 7, 2008 ª2008this protocol—causes injected cells to
lodge rapidly in the lungs and thus mirrors
the later steps of this cascade—survival
in the circulation, extravasation, and colo-
nization. As the authors observed, de-
layed activation of the transgenes after
cells had lodged in the lungs yielded
tumors with the histopathology and ro-
bust growth of those seen when autoch-
thonous tumors were initiated in the
orthotopic site—the mammary pad. The
same outcomes were observed when
mammary epithelial cells (MECs) bearing
the polyoma middle T oncogene were
introduced via the tail vein into the lungs
and then induced to express the trans-
genic oncogene.
Indeed, tail-vein-injected, phenotypi-
cally normal MECs could be seeded into
the lungs and allowed to persist there for
a period of 16 weeks before activation of
the transgenic oncogene. About 1 in
10,000 of such injected cells could be-
come established and survive in the lungs
without extensive proliferation and, with
high efficiency, generate tumors following
delayed, doxycycline-induced oncogene
activation. Moreover, when retrieved after
4 months of residence in the lungs, the
uninduced, phenotypically normal MECs
could form acinar structures in three-
dimensional in vitro cultures and generate
mammary ductal trees when implanted
in cleared mammary stromal fat pads.
These provocative observations raise
many questions. Are phenotypically nor-
mal cells from one organ routinely dis-
seminated to other sites in the human
body where they may settle and persist
for extended periods of time? If they do in-
deed survive in perfectly viable form, can
they undergo the changes in the distant
site needed to make them tumorigenic?
And if so, do the resulting metastases re-
semble those formed after cells undergo
transformation at a primary tumor site
and acquire the ability to disperse from
that site only later?
Responses to some of these questions
revolve around an issue raised earlier:
Does the development in a distant site of
high-grade malignant traits, such as colo-
nizing ability, require repeated rounds of
cell growth and division by already dis-
seminated cancer cells? And if so, can
relatively normal cells that have been
spontaneously disseminated to distant
sites undergo this proliferation—i.e., inElsevier Inc.addition to surviving in organs such as
the lungs, do they proliferate enough
there to undergo significant genetic and
epigenetic evolution?
In fact, the traditional order of invasive-
ness in the primary tumor as an obligatory
precursor to metastatic dissemination
has been upset by other experiments
reported in recent years. For example,
research by others on two strains of trans-
genic mice that are prone to develop
mammary carcinomas has shown un-
equivocal evidence of disseminated tu-
mor cells present in the bone marrow at
a time when only atypical ductal hyperpla-
sia (ADH, a benign stage) was present in
the mammary glands of one mouse strain
and occasional ductal carcinomas in situ
(DCIS) and ADH in the other (Husemann
et al., 2008). These other findings raise
the possibility that relatively benign dis-
seminated cancer cells can evolve into
macroscopic metastases, i.e., that the
genetic and epigenetic evolution of these
cells can take place at sites far removed
from the primary tumor. Moreover, these
papers, when taken together, open our
eyes to the possibility that metastatic dis-
semination occurs continually throughout
the course of primary tumor development,
yielding a diverse spectrum of dissemi-
nated cells, including ones that are at
the moment of dissemination almost
indistinguishable from normal cells.
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